α7 Helix Region of α1 Domain Is Crucial for Integrin Binding to Endoplasmic Reticulum Chaperone gp96

A POTENTIAL THERAPEUTIC TARGET FOR CANCER METASTASIS*

Received for publication, March 12, 2013, and in revised form, April 30, 2013 Published, JBC Papers in Press, May 13, 2013, DOI 10.1074/jbc.M113.468850

Feng Hong†, Bei Liu†, Gabriela Chiossi‡, Daniel T. Gewirth§, and Zihai Li††

From the †Department of Microbiology & Immunology, Medical University of South Carolina, Charleston, South Carolina 29425, the ‡Hauptman-Woodward Medical Research Institute, Buffalo, New York 14203, and the §Department of Molecular Pharmacology & Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10065

Background: Integrins are chaperoned by gp96, but the binding region to gp96 remains unknown.

Results: Deletion of α7 helix from α1 domain of integrin abolished the interaction between integrin and gp96. Targeting this region by corresponding peptide blocked cell invasion.

Conclusion: We successfully mapped the binding region of integrin to gp96.

Significance: This study will facilitate the development of new cancer therapeutics.

Integrins play important roles in regulating a diverse array of cellular functions crucial to the initiation, progression, and metastasis of tumors. Previous studies have shown that a majority of integrins are folded by the endoplasmic reticulum chaperone gp96. Here, we demonstrate that the dimerization of integrin α1 and β2 is highly dependent on gp96. The α1 domain (AID), a ligand binding domain shared by seven integrin α-subunits, is a critical region for integrin binding to gp96. Deletion of AID significantly reduced the interaction between integrin α1 and gp96. Overexpression of AID intracellularly decreased surface expression of gp96 clients (integrins and Toll-like receptors) and cancer cell invasion. The α7 helix region is crucial for AID binding to gp96. A cell-permeable α7 helix peptide competitively inhibited the interaction between gp96 and integrins and blocked cell invasion. Thus, targeting the binding site of α7 helix of AID on gp96 is potentially a new strategy for treatment of cancer metastasis.

Integrins are a large family of cell surface type I transmembrane receptors that mediate adhesion to the extracellular matrix and immunoglobulin superfamily molecules. At least 24 integrin heterodimers are formed by the combination of 18 α-subunits and 8 β-subunits (1). A wide variety of integrins have been shown to promote cancer cell proliferation, invasion, and survival. For example, in melanoma, the αV subunit has been found to be strongly expressed in both benign and malignant lesions, whereas the β3 subunit is exclusively expressed in vertical growth stage and metastatic disease (2, 3). In addition, increased expression of the integrin α6β4 stimulates the survival of breast cancer cells (4, 5), and elevated expression of integrin α5β1 correlates with decreased survival in patients with lymph node-negative non-small-cell lung carcinoma (6). Moreover, integrin α1L is up-regulated in CD44 stimulation-induced adhesion of colon cancer cells (7), and integrin α1L, αX, β1, β2, and ICAM are highly expressed in marginal zone B-cell lymphoma (8, 9). Furthermore, integrins on cancer stem cells have also been reported to play essential roles for cancer initiation and progression (10). In recent years, novel insights into the mechanisms that regulate tumor progression have led to the development of integrin-based therapeutics for cancer treatment. Integrin inhibitors, including antibodies, peptides, and nonpeptidic molecules, are considered to have direct and indirect antitumor effects by restricting tumor growth and blocking angiogenesis. Several inhibitors have shown promise in preclinical studies and phase I and phase II trials, but phase III trials have reached no clinically significant results (11–13). Vitaxin, a specific monoclonal antibody that targets the αvβ3 integrin, has shown significant antiangiogenic effects in preclinical studies and phase I/II trials (14–16). However, phase III trials have thus far shown no significant clinical benefits. Cilengitide is an l-arginine-glycine-l-aspartic acid-based peptide which antagonizes αvβ3 integrins and has been administered to patients with cancers of the breast, lung, and head and neck, but the results of those trials were not sufficiently encouraging to indicate further use in clinical practice (17, 18). Thus, novel integrin inhibitors for cancer therapy need to be discovered.

gp96 (also known as grp94, endoplasmic, and HSP90b1) is the ER-resident member of the Hsp90 family. Its expression is up-regulated by metabolic stress or the unfolded protein response, which results from the accumulation of misfolded proteins in the ER (19–21). gp96 has been implicated in cancer biology. Clinically, gp96 expression correlates with advanced stage and poor survival in a variety of cancers and is closely linked to cancer growth and metastasis in melanoma, breast, prostate, multiple myeloma, lung cancer, and colon cancer (22–25).
Definition of Binding Region of Integrin to gp96

29), gp96 has also been found to confer decreased sensitivity to x-ray irradiation (30), and it is required for the canonical Wnt pathway (31).

Recently, our group showed that the maturation of a majority of integrins is dependent on gp96, which folds integrins in the ER and controls their surface expression (32–34). In addition, we have identified a C-terminal loop structure formed by residues 652–678 of gp96 that constitutes the critical client-binding domain for chaperoning both integrins and the Toll-like receptor (35). Interestingly, we previously showed that all of the integrin \( \alpha \) subunits that contain the \( \alpha \) domain (AID) are gp96-dependent, suggesting that this domain may play an important role in the gp96-mediated cell surface expression of integrins (33). In this study, we have confirmed this hypothesis and, furthermore, demonstrated that AID is a critical region for integrin binding to gp96. Finally, we show that the AID-based TAT-tagged peptide inhibitor disrupts the interaction between integrins and gp96 and blocks cancer cell invasion.

EXPERIMENTAL PROCEDURES

Cell Lines—All gp96 mutant-transduced PreB leukemia cell lines were generated from parental gp96-null E4.126 PreB cell line, which was a kind gift from Dr. Phineas (Harvard University). RAW 264.7 leukemia cell and HCT116 colon cancer cell lines were purchased from ATCC. Phoenix Eco packaging cell line from ATCC was used for retrovirus production. All culture conditions have been previously described in Ref. 36.

Antibodies, Reagents, and Peptides—gp96 N terminus antibody 9G10 and gp96 C terminus antibody SPA851 were purchased from Enzo Life Sciences and detected both endogenous and overexpressed proteins. \( \beta \)-Actin antibody, Myc (9E10), and FLAG antibody were from Sigma Aldrich. HA antibody (clone 316–327 of integrin \( \alpha \) subunit) and overexpressed proteins. TAT-(clone M18/2), TLR2 (clone 6C2), and TLR4 (clone MTS510) were purchased from Covance, Inc. Biotin-conjugated FLAG antibody were from Sigma Aldrich. HA antibody (clone M18/2), TLR2 (clone 6C2), and TLR4 (clone MTS510) antibodies used for flow cytometry were purchased from eBioscience and detected endogenous proteins. TAT-\( \alpha \)p7, peptide, containing TAT sequence (YGRKRRQRRR) and amino acids 316–327 of integrin \( \alpha \), was synthesized by NEO Biolab to >98% purity as verified by HPLC and mass spectrometry. Other reagents were obtained from Sigma–Aldrich unless otherwise specified. H39, a gp96-specific Hsp90 inhibitor of the purine scaffold class, was synthesized using the protocol described in Ref. 37.

Constructs and Site-directed Mutagenesis—Wild type murine integrin \( \alpha \)L and \( \beta \)2 cDNA were used as templates for all PCR. Primers for integrin \( \alpha \)L are 5’- ATTAGCCGCCGCGGACACCTAGGTTCCTGGAATGCGG-3’ and 5’-TAATGCCTTCTTTCTCAGA TGCTTTGTCACTCTCCCGGAGG-3’. Primers for integrin \( \beta \)2 are 5’-ATTAGCGCCGCGCCACCATGCTGGGCCCA-3’ and 5’-TAATGCCTTCTTTCTCAGA TGCTTTGTCACTCTCCCGGAGG-3’. Primers for integrin \( \alpha \)L-overexpressing RAW 264.7 (WT and gp96 KD) cells were incubated with methionine- and cysteine-free medium for 2 h, followed by pulsed with 110 \( \mu \)Ci \([35S] \)methionine at 37 °C for 1 h, and chased at 0, 1, 2, and 4 h. Cells were washed with PBS and lysed in PBS containing 5% SDS. Cells were freeze thawed three times to enhance lysis. 200 \( \mu \)g of lysate were immunoprecipitated by using anti-HA antibody, followed by SDS-PAGE and autoradiography.

Flow Cytometry—All staining protocol, flow cytometry instrumentation, as well as data analysis were performed as described previously without significant modifications (34, 36, 39). For cell surface staining, single cell suspension of living cells was obtained and washed with FACs buffer twice. Fc receptor blocking with or without serum blocking was performed depending on individual primary antibody used for staining. Primary and secondary antibodies staining were performed stepwise, with FACs buffer washing in between steps. Propidium iodide was used to gate out dead cells. Stained cells were acquired on a FACs Calibur or FACs verse (BD Biosciences) and analyzed using the Flowjo software (Tree Star).

GST Pulldown Assay—AID of mouse integrin and deletion mutants of \( \alpha \)7 helix region of AID were subcloned into pGEX-pMagEmcs vector. GST fusion proteins were isolated on glutathione-Sepharose 4B beads (Amersham Biosciences). Cell lysate was incubated with GST alone or with GST-AID in the presence of 20 mm HEPES, pH 7.2, 50 mm KCl, 5 mm MgCl2, 20 mm Na2MoO4, 0.5% Nonidet P-40, and 1 mm ATP, followed by incubation with glutathione-Sepharose 4B beads at 4 °C overnight, and then washed three times, boiled in Laemmli buffer, and resolved by SDS-PAGE.

Invasion Assay—Cells (1 \( \times \) 106) were seeded in the upper chamber of a 1% gelatin-coated Transwell membrane (Corning). At 15 h, cells were fixed in 90% ethanol for 10 min and stained with 1% crystal violet for 10 min. Cells in the lower chamber were eluted with 10% acetic acid for 10 min, and the cell number was determined by OD at 595 nm.

Statistical Analysis—The Student’s t test was used for statistical analysis. p < 0.05 was considered significant.

RESULTS

Formation of the Integrin Heterodimer Is gp96-dependent—To test whether gp96 is required for formation of the integrin heterodimer, we used shRNA to knock down gp96 in RAW...
264.7 macrophages. We found that both total and surface expression of αL and β2 were reduced in gp96 knockout RAW 264.7 cells (KD), compared with that in wild type cells transduced with empty vector (EV) (Fig. 1A). We further overexpressed HA-tagged integrin αL and Myc-tagged β2 were overexpressed in EV-transduced wild type (EV) and gp96 knockout (KD-1, KD-2) RAW 264.7 cells. Immunoprecipitation of HA-tagged integrin αL from EV and gp96 KD cells was done, followed by immunoblot (IB) for indicated proteins. Whole cell lysates (WCL) were used as control. C, immunoprecipitation of Myc-tagged integrin β2 from gp96 EV and KD (KD-1) cells, followed by immunoblot for indicated proteins. Whole cell lysates (WCL) were used as control. D, total lysates of HA-tagged αL-overexpressed EV-transduced and KD-1 RAW 264.7 cells were untreated or treated with endoglycosidase H (Endo H) or peptide-N-glycosidase F (PNGase F), followed by immunoblot for integrin αL using anti-HA antibody. E, EV and KD-1 cells were untreated or treated with 5 μg/ml tunicamycin (Tuni) for 12 h, followed by immunoprecipitation for integrin αL. WCLs were used as control. F, HA-tagged αL-overexpressed EV-transduced WT and KD-1 RAW 264.7 cells were pulse labeled with [35S]Met, followed by chasing with cold Met for the indicated time point and immunoprecipitation (IP) for αL-HA. The precipitated proteins were analyzed by SDS-PAGE and autoradiography.

αL binding to β2. However, αL-HA presented as a doublet in both EV-transduced WT and KD RAW 264.7 cells (Fig. 1B). The top band was the major form in EV-transduced WT cells, whereas the lower band was dominant in KD RAW 264.7 cells. The top band was shown to be resistant to endoglycosidase H treatment, suggesting that this is the mature cell surface form of αL-HA, whereas the lower band was sensitive to endoglycosidase H, indicating it as the immature ER form of αL-HA (Fig. 1D). Additionally, both bands were sensitive to peptide-N-glycosidase F, which cleaves the entire N-linked glycan. The immature ER αL-HA was also sensitive to tunicamycin, an N-linked glycosylation inhibitor, causing reduction in binding to gp96 even though tunicamycin induced gp96 up-regulation via unfolded protein response. However, the matured cell surface αL-HA was resistant to this blockade and had no change in forming the dimerization with β2-Myc (Fig. 1E). Our previous study showed that <5% of gp96 was super-glycosylated and preferentially binds to its client molecule such as TLR9. Massively increased gp96 upon tunicamycin treatment was deglycosylated and failed to interact with TLR9 (34). All of these observations suggest that N-linked glycosylation on both gp96 and its clients are required for their optimal interaction. We also performed the pulse-chase experiment to follow the newly synthesized αL-HA in gp96 KD cells. In EV-transduced WT cells, the mature αL-HA started to show up 1 h after chasing and had completely changed to the mature form 4 h later. However, in gp96 KD cells (KD), the level of αL-HA was dramatically reduced after 4-hour chasing, and a majority of αL-HA remained immature (Fig. 1F).

AID Is Crucial for the Interaction between Integrins and gp96—To determine whether AID is required for AID-containing integrin binding to gp96, we generated GST-tagged AID
proteins from six AID-contained integrins including α1, α2, αD, αE, αL, and αM subunits. We found that all six GST-tagged AID proteins bound to gp96 (Fig. 2A). Moreover, when AID was deleted from integrin αL, the deletion resulted in significantly reduced interaction between integrin αL and gp96 (Fig. 2B). These results suggested that AID is a major binding region for integrin association with gp96. To further define which region of AID is critical for binding gp96, sequential deletion mutants of AID were generated. α7 helix is composed of 12 amino acids. Deletion of this region (Δα7) resulted in failure of AID to bind to gp96, indicating that α7 is integral to the binding of AID to gp96 (Fig. 2C).

AID Overexpression Decreased Cell Invasion in Vitro—If AID is needed for integrin binding to gp96, then intracellular expression of isolated AID mini-protein in the ER should competitively bind to gp96, thereby reducing gp96 binding and surface expression of multiple endogenous clientele. To test this hypothesis, we overexpressed FLAG-tagged AID in RAW 264.7 cells by retroviral-mediated transduction (Fig. 3A) and found that surface expression of integrin αL, along with αM, β2, TLR2, and TLR4, was indeed decreased (Fig. 3B). In addition, AID-overexpressing cells also showed decreased cell invasion in a Transwell system (Fig. 3C).

Cell-permeable TAT-α7 Peptide Blocked Interaction between gp96 and Integrin αL—Because the α7 helix region is critical for AID binding to gp96, we synthesized a cell-permeable TAT-tagged α7 helix peptide to test whether or not it competes with the endogenous integrin αL. TAT is an HIV protein that plays a pivotal role in both the HIV-1 replication cycle and in the pathogenesis of HIV-1 infection. An HIV TAT-derived peptide enables the intracellular delivery of cargos of various sizes and physicochemical properties, including small particles, proteins, peptides, and nucleic acids (40). We performed a competition experiment by incubating cells with this TAT-α7 peptide for 24 h prior to cell lysis. We then performed IP analysis to examine the interaction between gp96 and HA-tagged αL integrin. We found that TAT-α7 peptide inhibited the ability of gp96 to interact with αL-HA (Fig. 4A). This further supports the suggestion that there is a direct interaction between gp96 and the AID of αL integrin through the α7 helix region. In further support of this hypothesis, we also found that TAT-α7 peptide partially blocked surface expression of integrin αL, αM, and α4, but not β1 (Fig. 4B).

CD44 cross-linking on cancer cells has been shown to increase the cell surface expression of integrin αL, resulting in increased cancer invasion (7). To determine whether the α7 helix peptide reduces CD44 cross-linking induced surface expression of integrin αL, we treated the human colon cancer cell line, HCT116, with 10 μM TAT-α7 helix peptide. Such treatment resulted in complete abrogation of CD44-stimulated αL expression (Fig. 4C).

TAT-α7 Helix Peptide Prevented Cell Invasion in Vitro—Next, we tested whether TAT-α7 helix peptide can inhibit cell survival and invasion. As shown in Fig. 5A, a PreB leukemia cell line was treated with the indicated doses of TAT-α7 helix peptide, which had little effect on cell survival. However, when PreB and RAW 264.7 cells were pretreated with 10 μM of TAT-α7 helix peptide and then incubated in a Transwell system, cell invasion showed significant compromise, compared with PBS-treated cells (Fig. 5B). This reduced invasion was also
Definition of Binding Region of Integrin to gp96

FIGURE 5. \(\alpha_7\) helix peptide blocked cell invasion. A, PreB leukemia cells were treated with the indicated concentrations of TAT-\(\alpha_7\) helix peptide. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was carried out. B, PreB and RAW264.7 cells were pretreated with PBS or 10 \(\mu\)M TAT-\(\alpha_7\) helix peptide for 12 h and then were incubated in a Transwell chamber for an additional 15 h to measure cell invasion. *, \(p < 0.05\). C, RPMI 8226 myeloma cells were treated with PBS, 10 \(\mu\)M TAT-\(\alpha_7\) helix peptide, 5 \(\mu\)M H39 or TAT-\(\alpha_7\) plus H39 for 12 h, and then the Transwell assay was performed. *, \(p < 0.05\). D, HCT116 cells were pretreated with 10 \(\mu\)M TAT-\(\alpha_7\) peptide for 12 h and then seeded into a Transwell chamber and incubated with control 2nd antibody (Ab) or CD44 antibody with/without a 12-h pretreatment of TAT-\(\alpha_7\) peptide for 12 h. The numbers of invaded cells were counted. *, \(p < 0.05\).

observed in CD44 antibody-treated HCT116 cells with a pretreatment of the TAT-\(\alpha_7\) helix peptide (Fig. 5D). We also tested whether this novel peptide inhibitor can potentiate the anti-tumor effect of H39, a gp96-specific Hsp90 inhibitor of the purine scaffold class (41). H39 inhibits gp96 by directly binding to the ATP-binding pocket but not the client-binding domain of gp96. We found that the TAT-\(\alpha_7\) helix peptide and gp96-specific inhibitor, H39, had at least an additive effect on preventing invasion of RPMI 8226 human myeloma cells (Fig. 5C).

DISCUSSION

Many integrin-based inhibitors have thus far been introduced to the field for cancer therapy. However, these inhibitors only showed promising results in some preclinical studies, phase I/II clinical trials but largely failed during clinical phase III trials (11–17). The failure of these phase III trials can be ascribed to three causes. 1) It is difficult to deliver the antibodies or peptides to tumors in humans even though preclinical studies show that the drugs have benefits in animal models. 2) Integrin blockade is incomplete due to dose, affinity, or accessibility problems. 3) Most of the inhibitors block the function of a single integrin, and it is possible that blocking multiple integrins could have better therapeutic effects. However, this approach has proven to be difficult because most of the current integrin inhibitors are designed to compete with the ligands that bind to specific integrins. Such a strategy still allows for some ligand binding to other integrins that could trigger the outside-in signaling cascade in tumor cells. Our study is the first to show that AID is required for the interaction between integrin and gp96 (Fig. 2, A and B) and that the \(\alpha_7\) helix of AID is critical for binding to gp96 (Fig. 2C). Of particular interest, gp96 plays a key role in the folding and cell surface expression of multiple integrin subunits, including \(\alpha_1\), \(\alpha_2\), \(\alpha_4\), \(\alpha_D\), \(\alpha_L\), \(\alpha_M\), \(\alpha_X\), \(\alpha_Y\), \(\alpha_E\), \(\beta_2\), \(\beta_5\), \(\beta_6\), \(\beta_7\) and \(\beta_8\) (32, 34, 35, 42), many of which are critically required for tumor growth and metastasis (2–9). In this study, we found that competitive blocking of the gp96-integrin interaction by TAT-\(\alpha_7\) helix peptide decreased surface expression and maturation of not only integrin \(\alpha_L\) but also of other integrins (i.e. \(\alpha_M\) and \(\alpha_4\)) (Fig. 4, B and C). Our unique strategy thus allows us to target multiple integrins simultaneously, which is based on integrin substrate-derived peptide to occupy the client-binding site of gp96 to impair maturation of other gp96 clients. We have previously demonstrated that the residues 652–678 of client-binding domain of gp96 are critical for its binding to both integrins and TLRs (35). Thus, it is tempting to speculate that TAT-\(\alpha_7\) helix peptide binds and blocks the 652–678 region of the client-binding domain. Further structural studies should not only define the structural basis of gp96-integrin interaction but also facilitate the rational design of inhibitors against this pathway for cancer therapy.

As a proof-of-principle experiment, we found that TAT-\(\alpha_7\) helix peptide caused reduction of cell surface expression of multiple integrins (Fig. 4, B and C), as well as blocked cancer cell invasion in vitro (Fig. 5). Further studies are necessary to improve the druggability of this compound, including enhancing its intracellular delivery, its binding affinity to gp96, and its \(in vivo\) bioavailability and anti-cancer activity. Notwithstanding, chaperone-based and client-specific inhibitors could potentially hold a promise as a new class of therapeutics against cancer in the future.

Acknowledgments—We thank the past and present members in the Li laboratory for insightful discussions during the course of this work.

REFERENCES

1. Barczyk, M., Carracedo, S., and Gullberg, D. (2010) Integrins. Cell Tissue Res. 339, 269–280
2. Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R., Damjanovich, L., Herlyn, M., and Buck, C. A. (1990) Integrin distribution in malignant melanoma: association of the \(\beta_3\) subunit with tumor progression. Cancer Res. 50, 6757–6764
3. Natali, P. G., Hamby, C. V., Felding-Habermann, B., Liang, B., Nicotra, M. R., Di Filippo, F., Giannarelli, D., Temponi, M., and Ferrone, S. (1997) Clinical significance of \(\alpha_\beta_3\) integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57, 1554–1560
4. Weaver, V. M., Lelièvre, S., Lakins, J. N., Chreenek, M. A., Jones, J. C., Giancotti, F., Werb, Z., and Bissell, M. J. (2002) \(\beta_4\) integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2, 205–216
5. Guo, W., Pylaeva, Y., Pepe, A., Yoshioioka, T., Muller, W. J., Inghirami, G., and Giancotti, F. G. (2006) \(\beta_4\) integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126, 489–502
6. Dingeman, A. M., van den Boogaart, V., Vosse, B. A., van Suylen, R. J., Griffioen, A. W., and Thijssen, V. L. (2010) Integrin expression profiling identifies integrin \(\alpha_5\) and \(\beta_1\) as prognostic factors in early stage non-small cell lung cancer. Mol. Cancer 9, 152
7. Fujisaki, T., Tanaka, Y., Fujii, K., Mine, S., Saito, K., Yamada, S., Yamashita, U., Irimura, T., and Eto, S. (1999) CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins. Cancer Res. 59, 4427–4434
8. Vincent, A. M., Cawley, J. C., and Burthem, J. (1996) Integrin function in chronic lymphocytic leukemia. Blood 87, 4780–4788
Definition of Binding Region of Integrin to gp96

10. Pontier, S. M., and Muller, W. J. (2009) Integrons in mammary-stem-cell biology and breast-cancer progression—a role in cancer stem cells? J. Cell Sci. 122, 207–214

23. Missotten, G. S., Journée-de Korver, J. G., de Wolff-Rouendaal, D., Burkhart, D. J., Kalet, B. T., Coleman, M. P., Post, G. C., and Koch, T. H. (2000) Role of heat shock protein gp96 in the ER quality control: redundant or unique function? Mol. Cells 20, 173–182

25. Wu, M., Bai, X., Wang, D., Jiang, G., Wang, J., and Zhang, G. (2002) Molecular cloning, identification and analysis of lung squamous cell carcinoma-related genes. Lung Cancer 38, 235–241

27. Heike, M., Frenzel, C., Meier, D., and Galle, P. R. (2000) Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer. Int. J. Cancer 86, 489–493

40. Zhao, M., and Weissleder, R. (2004) Intracellular cargo delivery using tat fuses early T and B lymphopoiesis. Clin. Cancer Res. 10, 215–226

41. Taldone, T., and Chiosis, G. (2009) Purine-scaffold Hsp90 inhibitors. Curr. Top. Med. Chem. 9, 1436–1446

42. Morales, C., Wu, S., Yang, Y., Hao, B., and Li, Z. (2009) Drosophila glycoprotein 93 Is an ortholog of mammalian heat shock protein gp96 (grp94, HSP90b1, HSPC4) and retains disulfide bond-independent chaperone function for TLRs and integrins. J. Immunol. 183, 5121–5128